Table 2 Summary of ongoing clinical trials with ICI in solid tumor with brain metastasesa
Clinical trial identifier | Trial Name | Phase | Status |
|---|---|---|---|
NCT03175432 | Study of Bevacizumab in Combination With Atezolizumab in Patients With Untreated Melanoma Brain Metastases (BEAT-MBM) | II | Recruiting |
NCT02460068 | A Study of Fotemustine (FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (NIBIT-M2) | III | Recruiting |
NCT03340129 | Anti-PD 1 Brain Collaboration + Radiotherapy (ABC-X Study) (ABC-X) | II | Not yet recruiting |
NCT03728465 | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | II | Recruiting |
NCT02681549 | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer | II | Recruiting |
NCT02858869 | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | I | Recruiting |
NCT03563729 | Melanoma Metastasized to the Brain and Steroids (MEMBRAINS) | II | Recruiting |
NCT03873818 | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | II | Recruiting |
NCT02130466 | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) (patients with inactive brain metastases eligible) | I/II | Recruiting |
NCT02696993 | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | I/II | Recruiting |
NCT02978404 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | II | Recruiting |
NCT02886585 | Pembrolizumab In Central Nervous System Metastases | II | Recruiting |
NCT03867175 | Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer | III | Not yet Recruiting |
NCT03719768 | Avelumab With Radiotherapy in Patients With Leptomeningeal Disease | I | Recruiting |
NCT03325166 | Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases | II | Recruiting |
NCT02648477 | Pembrolizumab and doxorubicin hydrochloride or anti-estrogen therapy in treating patients with triple-negative or hormone receptor-positive metastatic breast cancer | II | Recruiting |
NCT03483012 | Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis | II | Recruiting |
NCT03449238 | Pembrolizumab And Stereotactic Radiosurgery (SRS) Of Selected Brain Metastases In Breast Cancer Patients | I/II | Recruiting |
NCT03526900 | Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis (ATEZO-BRAIN) | II | Recruiting |